In the article by Taramasso et al. entitled Management of Tricuspid Regurgitation: The Role of Transcatheter Therapies (Interventional Cardiology Review 2017;12(1):51–5. https://doi.org/10.15420/icr.2017:3:2), the following correction should be made.
The authors’ conflicts of interest were omitted at the time of publication. They should read as follows:
Maurizio Taramasso is a consultant for Abbott Vascular, Boston Scientific and 4tech; received personal fees from Edwards Lifesciences, Mitraltech, CoreMedic and Swissvortex; and is a shareholder of 4Tech.
Fabian Nietlispach serves a consultant for Edwards Lifesciences, Abbott, Medtronic and St Jude Medical.
Michel Zuber is a consultant for Abbott and Edwards Lifesciences.
Francesco Maisano discloses grant and/or research support from Abbott, Medtronic, Edwards Lifesciences, Biotronik, Boston Scientific, NVT and Terumo; consulting fees and honoraria from Abbott, Medtronic, Edwards Lifesciences, Swissvortex, Perifect, Xeltis, Transseptal Solutions, Cardiovalve (Mitraltech) and Magenta; royalty income/IP rights from Edwards Lifesciences; and is a shareholder of Cardiogard, Magenta, SwissVortex, Transseptalsolutions, Occlufit, 4Tech and Perifect.
All other authors have no conflicts of interest to declare.
The authors apologise for this error.